WO2007030708A3 - Antimicrobial adzymes and uses thereof - Google Patents
Antimicrobial adzymes and uses thereof Download PDFInfo
- Publication number
- WO2007030708A3 WO2007030708A3 PCT/US2006/035011 US2006035011W WO2007030708A3 WO 2007030708 A3 WO2007030708 A3 WO 2007030708A3 US 2006035011 W US2006035011 W US 2006035011W WO 2007030708 A3 WO2007030708 A3 WO 2007030708A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adzymes
- methods
- antimicrobial
- disease
- termed
- Prior art date
Links
- 230000000845 anti-microbial effect Effects 0.000 title 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Disclosed is a family of novel protein constructs, useful as antimicrobial agents, termed 'adzymes,' comprising an address moiety and a catalytic domain. The present invention also provides pharmaceutical compositions comprising these adzymes, methods of making adzymes, DNA's encoding adzymes or parts thereof, and methods of using adzymes, such as for treating human subjects suffering from a disease, such as an infectious disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71511005P | 2005-09-08 | 2005-09-08 | |
US60/715,110 | 2005-09-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007030708A2 WO2007030708A2 (en) | 2007-03-15 |
WO2007030708A3 true WO2007030708A3 (en) | 2008-01-17 |
Family
ID=37836512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/035011 WO2007030708A2 (en) | 2005-09-08 | 2006-09-08 | Antimicrobial adzymes and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007030708A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201805253SA (en) | 2016-01-11 | 2018-07-30 | Rubius Therapeutics Inc | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
WO2019017937A1 (en) | 2017-07-19 | 2019-01-24 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for cardiometabolic disease |
WO2019017940A1 (en) | 2017-07-19 | 2019-01-24 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for infectious disease |
US20190290686A1 (en) | 2017-12-23 | 2019-09-26 | Rubius Therapeutics, Inc. | Artificial antigen presenting cells and methods of use |
CN113366102A (en) | 2018-12-03 | 2021-09-07 | 鲁比厄斯治疗法股份有限公司 | Artificial antigen presenting cells comprising HLA-E and HLA-G molecules and methods of use |
WO2020172472A1 (en) | 2019-02-20 | 2020-08-27 | Rubius Therapeutics, Inc. | Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use |
WO2022055902A2 (en) * | 2020-09-08 | 2022-03-17 | Curie Co. Inc. | Compositions and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004019878A2 (en) * | 2002-08-27 | 2004-03-11 | Compound Therapeutics, Inc. | Adzymes and uses thereof |
WO2005085430A2 (en) * | 2004-03-02 | 2005-09-15 | Compound Therapeutics, Inc. | Adzymes and uses thereof |
-
2006
- 2006-09-08 WO PCT/US2006/035011 patent/WO2007030708A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004019878A2 (en) * | 2002-08-27 | 2004-03-11 | Compound Therapeutics, Inc. | Adzymes and uses thereof |
WO2005085430A2 (en) * | 2004-03-02 | 2005-09-15 | Compound Therapeutics, Inc. | Adzymes and uses thereof |
Non-Patent Citations (4)
Title |
---|
MELEKHOVETS Y F ET AL: "Fusion with an RNA binding domain to confer target RNA specificity to an RNase: design and engineering of Tat-RNase H that specifically recognizes and cleaves HIV-1 RNA in vitro", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 24, no. 10, 1996, pages 1908 - 1912, XP002904225, ISSN: 0305-1048 * |
MIKLOS SAHIN-TOTH: "ADDRESSABLE ENZYMES AS PROTEIN THERAPEUTICS", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 16, no. 5, 2006, pages 719 - 721, XP002391579, ISSN: 1354-3776 * |
RUNGE M S ET AL: "HYBRIDS MOLECULES INSIGHTS INTO PLASMINOGEN ACTIVATOR FUNCTION", MOLECULAR BIOLOGY AND MEDICINE, LONDON, GB, vol. 8, no. 2, 1991, pages 245 - 255, XP009069917 * |
SZMOLA RICHÁRD ET AL: "Human mesotrypsin is a unique digestive protease specialized for the degradation of trypsin inhibitors", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 278, no. 49, 5 December 2003 (2003-12-05), pages 48580 - 48589, XP002342456, ISSN: 0021-9258 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007030708A2 (en) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005032471A3 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2004062625A3 (en) | Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease | |
WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2005019258A3 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2005004802A3 (en) | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2005065195A3 (en) | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2007011833A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2005018545A3 (en) | Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2005051914A8 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
EP1841426A4 (en) | Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease | |
EP2213684A3 (en) | Nogo-a antibodies for the treatment of Alzheimer disease | |
DE60028970D1 (en) | AT HER2 BINDING PEPTIDE COMPOUNDS | |
EP2450359A3 (en) | (R)-N-Methylnaltrexone | |
WO2004047728A3 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2004039956A3 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2006044497A3 (en) | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease | |
EA200700202A1 (en) | Heteroaryl compounds as betamimetics for the treatment of respiratory tract diseases | |
WO2005090296A3 (en) | N-substituted benzene sulfonamides | |
WO2005014035A3 (en) | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest | |
WO2006124748A3 (en) | Multicyclic compounds and methods of their use | |
HK1092467A1 (en) | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n- | |
WO2006086562A3 (en) | Phenylazetidinone derivatives | |
WO2004019878A3 (en) | Adzymes and uses thereof | |
WO2007030708A3 (en) | Antimicrobial adzymes and uses thereof | |
WO2005046603A3 (en) | Pyridine compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06790200 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06790200 Country of ref document: EP Kind code of ref document: A2 |